Melanie Gloria sold $72k of IMVT
Chief Operating Officer at Immunovant, Inc.. 2,241 shares at an average of $32.06, traded Oct 7, 2026, filed Oct 9, 2026.
Score components
- +20RoleCOO
- +8Trade size$72k at market
- 0Share of holdings soldSold 1.0% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001764013-26-000112, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 7, 2026 | SOpen-market sale Common Stock | -2,241 | $32.06 | $72k | 217,060 | 3 d ago |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| 36Weak | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 29Weak | IMVTsell Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $291k 10,813 shares | -7% | |
| 43Moderate | IMVTbuy Immunovant, Inc. | Roivant Sciences Ltd. director, owner | $350M 16,666,666 shares | +17% | |
| 33Weak | Immunovant, Inc. | Andrew J. Fromkin director | $517k 22,249 shares | -21% | |
| 30Weak | Immunovant, Inc. | Douglas J. Hughes director | $349k 15,000 shares | -11% | |
| 49Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $298k 12,626 shares | -7% | |
| 30Weak | Immunovant, Inc. | Michael Geffner Chief Medical Officer | $49k 2,595 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.